Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | PYGM | P11217 | 4/20 | 0.46 |
| ▸ | PYGL | P06737 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604342 | 0.91 | KDM4E (0.49) | MTNR1BPOLBL3MBTL1ATMKDM4E | |
| SCHEMBL4604249 | 0.91 | POLB (0.54) | MTNR1BPOLBL3MBTL1ATMKDM4E | |
| SCHEMBL4603669 | 0.86 | ALDH1A1 (0.53) | MTNR1BPOLBL3MBTL1ATMKDM4E | |
| SCHEMBL4604961 | 0.85 | ALDH1A1 (0.48) | MTNR1BPOLBL3MBTL1ATMKDM4E | |
| SCHEMBL4603683 | 0.84 | PYGM (0.62) | PYGMPYGL | |
| SCHEMBL4606880 | 0.83 | KMT2A (0.57) | MTNR1BPOLBL3MBTL1ATMKDM4E | |
| SCHEMBL4605334 | 0.83 | KDM4E (0.52) | POLBL3MBTL1KDM4EALDH1A1PKM | |
| SCHEMBL4605144 | 0.83 | KDM4E (0.49) | POLBKDM4EALDH1A1PKMHSD17B10 | |
| SCHEMBL4605135 | 0.82 | KDM4E (0.49) | POLBL3MBTL1KDM4EALDH1A1PKM | |
| SCHEMBL4606525 | 0.82 | CTSV (0.47) | MTNR1BPOLBL3MBTL1ATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1720825-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Active Biotech AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
| WO-2005075410-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | MTNR1B 1361/4885POLB 2352/4885L3MBTL1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.